Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?
- PMID: 29478869
- PMCID: PMC6107444
- DOI: 10.1053/j.ajkd.2017.12.007
Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?
Abstract
Patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) are 10 times more likely to die of cardiovascular (CV) diseases than the general population, and dialysis-dependent patients are at even higher risk. Although traditional CV risk factors are highly prevalent in individuals with CKD, these patients were often excluded from studies targeting modification of these risks. Although treatment of hypertension is beneficial in CKD, the best target blood pressure has not been established. Trial data showed that renin-angiotensin-aldosterone blockade may prevent CV events in patients with CKD. The risks of aspirin may equal the benefits in NDD-CKD samples, and there are no trials testing aspirin in dialysis-dependent patients. Lipid-lowering therapy improves CV outcomes in NDD-CKD, but not in dialysis-dependent patients. Strict glycemic control prevents CV events in nonalbuminuric individuals, but showed no benefit in those with baseline albuminuria with albumin excretion > 300mg/g, and there are no data in dialysis-dependent patients. Data for lifestyle modifications, such as weight loss, physical activity, and smoking cessation, are mostly observational and extrapolated from non-CKD samples. This comprehensive review summarizes the best existing evidence and current clinical guidelines for modification of traditional risk factors for the prevention of CV events in patients with CKD and identifies knowledge gaps.
Keywords: Chronic kidney disease (CKD); RAAS blockade; albuminuria; aspirin; cardiovascular disease (CVD); cardiovascular risk; dialysis; hemodialysis (HD); hyperlipidemia; hypertension; lifestyle interventions; modifiable risk factor; review; smoking; statin; weight loss.
Published by Elsevier Inc.
Conflict of interest statement
Financial Disclosure: The authors declare that they have no revelant financial interests.
Figures

Similar articles
-
Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease.Curr Atheroscler Rep. 2019 Jun 22;21(9):32. doi: 10.1007/s11883-019-0794-6. Curr Atheroscler Rep. 2019. PMID: 31230129 Review.
-
Cardiovascular disease and its relationship with chronic kidney disease.Eur Rev Med Pharmacol Sci. 2014 Oct;18(19):2918-26. Eur Rev Med Pharmacol Sci. 2014. PMID: 25339487 Review.
-
Is lipid management effective for all stages of CKD?Blood Purif. 2013;35(1-3):26-30. doi: 10.1159/000345932. Epub 2013 Jan 22. Blood Purif. 2013. PMID: 23343543 Review.
-
Statins for treatment of dyslipidemia in chronic kidney disease.Perit Dial Int. 2006 Sep-Oct;26(5):523-39. Perit Dial Int. 2006. PMID: 16973506 Review.
-
Statin use in patients with diabetes and kidney disease: the Japanese experience.J Atheroscler Thromb. 2013;20(5):407-24. doi: 10.5551/jat.16261. Epub 2013 Mar 22. J Atheroscler Thromb. 2013. PMID: 23518468 Review.
Cited by
-
Association of Blood Pressure Variability and Diuretics With Cardiovascular Events in Patients With Chronic Kidney Disease Stages 1-5.Hypertension. 2021 Mar 3;77(3):948-959. doi: 10.1161/HYPERTENSIONAHA.120.16117. Epub 2021 Jan 11. Hypertension. 2021. PMID: 33423525 Free PMC article.
-
Prevalence of chronic kidney disease and its associated factors in Malaysia; findings from a nationwide population-based cross-sectional study.BMC Nephrol. 2020 Aug 14;21(1):344. doi: 10.1186/s12882-020-01966-8. BMC Nephrol. 2020. PMID: 32795256 Free PMC article.
-
Urea levels and cardiovascular disease in patients with chronic kidney disease.Nephrol Dial Transplant. 2022 Feb 26;38(1):184-92. doi: 10.1093/ndt/gfac045. Online ahead of print. Nephrol Dial Transplant. 2022. PMID: 35544273 Free PMC article.
-
Short-Chain Fatty Acids and Their Metabolic Interactions in Heart Failure.Biomedicines. 2025 Feb 3;13(2):343. doi: 10.3390/biomedicines13020343. Biomedicines. 2025. PMID: 40002756 Free PMC article. Review.
-
Natriuretic peptides, extracellular volume, and subclinical cardiovascular changes in chronic kidney disease stages 1-3: a pilot study.J Investig Med. 2022 Jul 19:jim-2022-002467. doi: 10.1136/jim-2022-002467. Online ahead of print. J Investig Med. 2022. PMID: 35853670 Free PMC article.
References
-
- United States Renal Data System. 2016 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda, MD: 2016.
-
- Mathew RO, Bangalore S, Lavelle MP, et al. Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a review. Kidney Int. 2016;91(4):797–807. - PubMed
-
- Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330(13):877–884. - PubMed
-
- Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365(9463):939–946. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical